BioWorld

March 22, 2005

Onyx, Bayer Plan To File NDA For Sorafenib On Interim Data

Onyx Pharmaceuticals Inc. and Bayer Pharmaceuticals Corp. plan to file for FDA approval of BAY 43-9006, which has been renamed sorafenib, based on interim Phase IIII data from a study in advanced kidney cancer patients. (BioWorld Today) Read More

Sequoia Raises $22M To Fund Programs In Viral Infections

Avastin Competitor Misses Endpoint; Genentech Jumps

Biolex Signs Up Centocor In Wide-Ranging Protein Deal

Other News To Note

U.S. Patent Disclosures

Today's news in brief

BioWorld

BioWorld briefs for Feb. 6, 2025.

MJFF grant supports Bexorg’s translational biomarker work

BioWorld Science

Bexorg Inc. has been awarded a research grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) through the Targets to Therapies initiative to...

REST emerges as biomarker in ALS, knockdown improves ALS symptoms

BioWorld Science

About 10% of amyotrophic lateral sclerosis (ALS) cases result from inherited genetic mutations, with about 20% of them attributed to mutations in the gene...

Serotonin receptor modulators for the treatment of OUD

BioWorld Science

Opioid use disorder (OUD) causes high morbidity and mortality rates, with fentanyl driving unprecedented overdose rates. Researchers from the University of...

KLF15 shows potential as marker, target for cholangiocarcinoma

BioWorld Science

Researchers at the Biodonostia Health Research Institute reported on the role of KLF15 in cholangiocarcinogenesis and its potential as a therapeutic target in...